Clinical implications of mutational analysis in gastrointestinal stromal tumours
- PMID: 18253129
- PMCID: PMC2259190
- DOI: 10.1038/sj.bjc.6604217
Clinical implications of mutational analysis in gastrointestinal stromal tumours
Abstract
The management of localised and advanced gastrointestinal stromal tumours (GISTs) in terms of histological diagnosis, surgery, imaging, medical treatment and molecular biology has rapidly changed since introduction of imatinib mesylate for molecularly targeted therapy in 2000. In this minireview, we briefly summarise and discuss the current data relevant to the increasing role of molecular characterisation of GISTs in the diagnosis, risk assessment and effective targeted therapy.
References
-
- Andersson J, Bumming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, Odén A, Gustavsson B, Kindblom LG, Nilsson B (2006) Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130: 1573–1581 - PubMed
-
- Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182–4190 - PubMed
-
- Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, Maki NDS, DeMatteo RP, Besmer B (2004) Gene expression in gatrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10: 3282–3290 - PubMed
-
- Bauer S, Yu LK, Demetri GD, Fletcher JA (2006) Heat-shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66: 9153–9161 - PubMed
-
- Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813–3825 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources